Immatics Raises €54 Million Series C To Fund Pivotal Therapeutic Cancer Vaccine Trial
This article was originally published in The Pink Sheet Daily
One of the largest European fundraisings this year, the round will help advance a potential therapeutic vaccine for kidney cancer through Phase III.
You may also be interested in...
With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.
A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.